The response rate of systemic chemotherapy for metastatic lymph nodes is low. This invention presents the optimal values for solvent properties, especially viscosity, in a method for directly administering drugs to lymph nodes (lymphatic drug delivery system). In 2024, a specified clinical study (jRCTs021230040) on lymph node metastasis was started at the Iwate Medical University Hospital Head and Neck Cancer Center.

In systemic chemotherapy for metastatic lymph nodes, the amount of drug delivered to the metastatic lymph nodes is small. This is due to the increase in internal pressure caused by tumor growth in the lymph nodes and the disappearance of microvessels caused by the formation of tumor mass. In this invention, we clarified the optimal viscosity range of the solvent for the lymphatic drug delivery system, which directly administers drugs to lymph nodes.

• The amount of anticancer drug required to treat one metastatic lymph node is 1/100 to 1/1000 of the systemic dose.
• The drug can be administered into the lymph node under ultrasound guidance.
• An international patent has been filed for the solvent of the administered drug.

1. Treatment and prophylactic therapy of affiliated lymph nodes in head and neck cancer, breast cancer, etc.
2. Pharmaceutical companies aiming to develop drugs by drug repositioning and generics
3. Medical device manufacturers aiming to develop a dosing system

• Lymph node
• regional lymph node
• lymph node metastasis
• breast cancer
• head and neck cancer
• anti-cancer drug
• immunity
• systemic chemotherapy